Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis

SK. Eskandari, H. Allos, BS. Al Dulaijan, G. Melhem, I. Sulkaj, JB. Alhaddad, AJ. Saad, C. Deban, P. Chu, JY. Choi, B. Kollar, B. Pomahac, LV. Riella, SP. Berger, JSF. Sanders, J. Lieberman, L. Li, JR. Azzi

. 2022 ; 13 (-) : 899975. [pub] 20220610

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22029617

Grantová podpora
R01 AI134842 NIAID NIH HHS - United States

Regulatory T cells (Tregs) have shown great promise as a means of cellular therapy in a multitude of allo- and auto-immune diseases-due in part to their immunosuppressive potency. Nevertheless, the clinical efficacy of human Tregs in patients has been limited by their poor in vivo homeostasis. To avert apoptosis, Tregs require stable antigenic (CD3ζ/T-cell-receptor-mediated), co-stimulatory (CD28-driven), and cytokine (IL-2-dependent) signaling. Notably, this sequence of signals supports an activated Treg phenotype that includes a high expression of granzymes, particularly granzyme B (GrB). Previously, we have shown that aside from the functional effects of GrB in lysing target cells to modulate allo-immunity, GrB can leak out of the intracellular lysosomal granules of host Tregs, initiating pro-apoptotic pathways. Here, we assessed the role of inhibiting mechanistic target of rapamycin complex 1 (mTORC1), a recently favored drug target in the transplant field, in regulating human Treg apoptosis via GrB. Using ex vivo models of human Treg culture and a humanized mouse model of human skin allotransplantation, we found that by inhibiting mTORC1 using rapamycin, intracytoplasmic expression and functionality of GrB diminished in host Tregs; lowering human Treg apoptosis by in part decreasing the phosphorylation of S6K and c-Jun. These findings support the already clinically validated effects of mTORC1 inhibition in patients, most notably their stabilization of Treg bioactivity and in vivo homeostasis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22029617
003      
CZ-PrNML
005      
20230113133329.0
007      
ta
008      
230113s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2022.899975 $2 doi
035    __
$a (PubMed)35757726
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Eskandari, Siawosh K $u Transplantation Research Center, Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States $u Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
245    10
$a mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis / $c SK. Eskandari, H. Allos, BS. Al Dulaijan, G. Melhem, I. Sulkaj, JB. Alhaddad, AJ. Saad, C. Deban, P. Chu, JY. Choi, B. Kollar, B. Pomahac, LV. Riella, SP. Berger, JSF. Sanders, J. Lieberman, L. Li, JR. Azzi
520    9_
$a Regulatory T cells (Tregs) have shown great promise as a means of cellular therapy in a multitude of allo- and auto-immune diseases-due in part to their immunosuppressive potency. Nevertheless, the clinical efficacy of human Tregs in patients has been limited by their poor in vivo homeostasis. To avert apoptosis, Tregs require stable antigenic (CD3ζ/T-cell-receptor-mediated), co-stimulatory (CD28-driven), and cytokine (IL-2-dependent) signaling. Notably, this sequence of signals supports an activated Treg phenotype that includes a high expression of granzymes, particularly granzyme B (GrB). Previously, we have shown that aside from the functional effects of GrB in lysing target cells to modulate allo-immunity, GrB can leak out of the intracellular lysosomal granules of host Tregs, initiating pro-apoptotic pathways. Here, we assessed the role of inhibiting mechanistic target of rapamycin complex 1 (mTORC1), a recently favored drug target in the transplant field, in regulating human Treg apoptosis via GrB. Using ex vivo models of human Treg culture and a humanized mouse model of human skin allotransplantation, we found that by inhibiting mTORC1 using rapamycin, intracytoplasmic expression and functionality of GrB diminished in host Tregs; lowering human Treg apoptosis by in part decreasing the phosphorylation of S6K and c-Jun. These findings support the already clinically validated effects of mTORC1 inhibition in patients, most notably their stabilization of Treg bioactivity and in vivo homeostasis.
650    _2
$a zvířata $7 D000818
650    12
$a apoptóza $7 D017209
650    _2
$a granzymy $x metabolismus $7 D053804
650    _2
$a lidé $7 D006801
650    _2
$a mTORC1 $x metabolismus $7 D000076222
650    _2
$a myši $7 D051379
650    _2
$a receptory antigenů T-buněk $x metabolismus $7 D011948
650    12
$a regulační T-lymfocyty $7 D050378
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Allos, Hazim $u Transplantation Research Center, Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
700    1_
$a Al Dulaijan, Basmah S $u Transplantation Research Center, Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
700    1_
$a Melhem, Gandolina $u Transplantation Research Center, Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
700    1_
$a Sulkaj, Ina $u Transplantation Research Center, Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States $u Graduate Program in Immunology, Johns Hopkins School of Medicine, Baltimore, MD, United States
700    1_
$a Alhaddad, Juliano B $u Transplantation Research Center, Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
700    1_
$a Saad, Anis J $u Transplantation Research Center, Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
700    1_
$a Deban, Christa $u Transplantation Research Center, Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
700    1_
$a Chu, Philip $u Transplantation Research Center, Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
700    1_
$a Choi, John Y $u Transplantation Research Center, Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
700    1_
$a Kollar, Branislav $u Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States $u Department of Plastic and Hand Surgery, University of Freiburg Medical Center, Medical Faculty of the University of Freiburg, Freiburg, Germany
700    1_
$a Pomahač, Bohdan, $u Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States $u Division of Plastic and Reconstructive Surgery, Smilow Cancer Hospital, Yale School of Medicine, New Haven, CT, United States $d 1971- $7 xx0117402
700    1_
$a Riella, Leonardo V $u Transplantation Research Center, Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States $u Center of Transplantation Sciences, Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States
700    1_
$a Berger, Stefan P $u Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
700    1_
$a Sanders, Jan S F $u Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
700    1_
$a Lieberman, Judy $u Program in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States $u Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
700    1_
$a Li, Li $u Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
700    1_
$a Azzi, Jamil R $u Transplantation Research Center, Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States $u Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 13, č. - (2022), s. 899975
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35757726 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230113 $b ABA008
991    __
$a 20230113133320 $b ABA008
999    __
$a ok $b bmc $g 1883737 $s 1180942
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 13 $c - $d 899975 $e 20220610 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
GRA    __
$a R01 AI134842 $p NIAID NIH HHS $2 United States
LZP    __
$a Pubmed-20230113

Najít záznam

Citační ukazatele

Možnosti archivace